News

Ihre Auswahl

produzieren / 05.01.2021
Single Mouse Trials: mimicking clinical phase II trials in PDX models with manageable costs and efforts

The long and successful collaboration of EPO with the Charité University Hospital in Berlin recently led to the following publication:

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer

The article has been published in the peer-reviewed journal Oncotarget (Oncotarget, 2020, Vol. 11, (No. 41), pp: 3688-3697).

Background

Head and neck squamous cell carcinoma (HNSCC) represents the 6th most common type of cancer and despite recent advances remains an area of high unmet medical need. Around 66% of HNSCCs harbor genomic alterations in one of the major components of the phosphoinositide 3-kinase (PI3K) signaling pathway, making PI3K an attractive target.

EPO´s contribution

EPO has established a thoroughly characterized panel of more than 70 HNSCC patient-derived xenograft (PDX) models (HPV +/-). To explore the activity of the PI3K inhibitor copanlisib in monotherapy and in combination with the EGFR inhibitor cetuximab, 33 PDX models were selected out of this panel for a mouse clinical trial together with Bayer AG.

How YOUR projects could benefit from it

We successfully applied the one mouse, one tumor, one treatment trial design on our HNSCC PDX panel to establish a sound preclinical rational for the evaluation of copanlisib in combination with cetuximab in a clinical setting. This demonstrates that a large number of heterogeneous tumors can be evaluated and a clinical phase II trial can be mimicked in PDX models with manageable costs and efforts.

Mouse clinical trials in oncology drug development

Around 85% of preclinical agents entering oncology clinical trials fail to demonstrate sufficient safety or efficacy to gain regulatory approval. This high failure rate highlights the continued limitations of the predictive value of existing preclinical models and clearly shows an urgent need for experimental systems that better replicate the diversity of human tumor biology in a preclinical setting. While PDX models faithfully recapitulate human tumor biology and predict patient drug response, studies with small numbers of models have limited value in predicting potential clinical-trial response at the population level. Mouse clinical trials (MCTs) are population-based efficacy studies mimicking human trials. For these, the single mouse study design is a feasible and very cost-effective approach to reliably screen a large numbers of models with diverse genetic characteristics.

Important considerations for your study

Similar to clinical trials, rational design of MCTs requires statistical power calculation and sample size determination, thus the number of mouse models as well as the number of mice per model needs to be carefully considered. In general, the study design depends on factors such as the study aims, the efficacy of the applied drugs and the available resources. For example, when there is only a limited number of suitable PDXs, e.g., PDXs carrying a particular mutation or PDXs of a specific subtype, the number of mice per PDX could be increased to boost statistical power. Our scientific and bioinformatics team will actively support you to tailor a study design specifically for your needs based on detailed statistical and bioinformatics analyses.

Possible applications

There is a broad variety of possible applications for single mouse trials. These include exploration of new drug combinations as demonstrated by our new publication, comprehensive analysis of one tumor entity, identification of biomarkers for predicting treatment responses, screening of a large number of compounds in diverse tumor populations and many more. Please reach out to learn more!

Source: EPO Gmbh Newsletter December 2020: Single Mouse Trials

epo-berlin.com

Alle News im Überblick

News Buch Berlin

Zukunftsfähige Ideen im Wettbewerb „Jugend forscht“

Das Immunsystem mit Kefirknollen stärken, intelligente Straßenmodelle entwickeln, ein Programm für chemische Reaktionen schreiben: Die Gewinner*innen des 56. Regionalwettbewerbs auf dem Campus Berlin-...

weiter ...

Umzug des Regional Sozialpädagogischen Dienstes (RSD) Region Nord

Eingeschränkte Erreichbarkeit vom 1. – 5. März 2021

weiter ...

Wie das Immunsystem SARS-CoV-2 den Weg ebnet

Mit antiviralen Botenstoffen will das Immunsystem SARS-CoV-2 eigentlich bekämpfen. Ein Forschungsteam von Charité und MDC hat nun gezeigt, wie ein solcher Botenstoff die Vermehrung des Virus begünstig...

weiter ...

Termine Buch Berlin

19.04.2021, 09:00 / Digitale Veranstaltung
Pharmacokinetics - Essentials for Project Managers in Biotech Companies

Basics in understanding pharmacokinetics in clinicial development - for non-physicians

weitere Informationen

14.09.2021, 09:00 / Gläsernes Labor
GMP Biotech Summer School

Good Manufacturing Practice (GMP) Basic Course Biotechnology (English)

weitere Informationen

Sponsoren der Website: